Merial will market and sell Zoetis’ products, including global/local brands such as Bovical, Lutalyse, Xnel Dectomax and vaccines like Rispoval and Spirovac. The products will be marketed by Merial India beginning in April 2016. Financial details of the agreement were not disclosed.
“The newly added products complement Merial’s existing ruminant business in India, which includes vaccines, therapeutics and nutritionals. It increases our presence in the important dairy segment and expands our current product offerings,” said Sandeep Karkhanis, country manager, Merial India.
“This agreement helps both companies use the strengths of our product portfolios and market strategies to grow in a more effective way.”
Growth in value-added dairy
Ketan Dhamanaskar, managing director, India, GM South Asia, Zoetis, said, “Zoetis’ leading dairy brands and innovative vaccines, combined with the strong distribution reach and presence of Merial in India, will enable us to make these products available in the most efficient manner in the Indian market.”
In 2014, the ruminant health market in India was valued at $265m (€240m).
According to a Credit Analysis & Research Limited report, the share of value-added dairy products in the milk and milk derivatives segment is growing by around 25% annually, and is expected to continue to grow at the same rate until 2019-20.